Added to YB: 2025-07-14
Pitch date: 2025-07-11
IOBT [bearish]
IO Biotech, Inc.
+44.68%
current return
Author Info
Biotenic is a freelance L/S biotech investment analyst sharing investment theses. Sign up for the newsletter.
Company Info
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
Market Cap
$54.5M
Pitch Price
$1.46
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.46
P/E
-0.62
EV/Sales
N/A
Sector
Biotechnology
Category
N/A
IOBT -- Ph3 Cylembio PFS Data Q3
IOBT short: Melanoma cancer vaccine targeting IDO, historically unsuccessful target & delivery method. POC data unconvincing - single-center trial showing PD-1 naive responses, but no activity in PD-1 progressors. Controlled trial missed ORR interim. Phase 3 PFS readout delayed, bad sign. $100M mcap but poor finances, loan tranches contingent on success.
Read full article (5 min)